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Abstract
Objectives—Small series have suggested that outcomes after abusive head trauma (AHT) are 
less favorable than after other injury mechanisms. We sought to determine the impact of AHT on 
mortality and identify factors that differentiate children with AHT from those with TBI from other 
mechanisms.
Design—First 200 subjects from the Approaches and Decisions in Acute Pediatric TBI (ADAPT) 
Trial – a comparative effectiveness study using an observational, cohort study design.
Setting—Pediatric intensive care units in tertiary children’s hospitals in USA and abroad.
Participants—Consecutive children (age <18 y) with severe TBI (GCS ≤ 8; intracranial pressure 
(ICP) monitoring).
Interventions—None
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Measurements and Main Results—Demographics, injury-related scores, prehospital and 
resuscitation events were analyzed. Children were dichotomized based on likelihood of AHT. A 
total of 190 children were included (n = 35 with AHT). AHT subjects were younger (1.87 y ± 0.32 
vs. 9.23 y ± 0.39, p < 0.001) and a greater proportion were female (54.3% vs. 34.8%, p = 0.032). 
AHT were more likely to (i) be transported from home (60.0% vs. 33.5%, p < 0.001), (ii) have 
apnea (34.3% vs. 12.3%, p = 0.002) and (iii) seizures (28.6% vs. 7.7%, p < 0.001) during pre-
hospital care. AHT had a higher incidence of seizures during resuscitation (31.4 vs. 9.7%, p = 
0.002). After adjusting for covariates, there was no difference in mortality (AHT, 25.7% vs. non-
AHT, 18.7%, HR 1.758, p = 0.60). A similar proportion died due to refractory intracranial 
hypertension in each group (AHT, 66.7% vs. non-AHT, 69.0%).
Conclusion—In this large, multicenter series, children with AHT had differences in prehospital 
and in-hospital secondary injuries which could have therapeutic implications. Unlike other TBI 
populations in children, female predominance was seen in AHT in our cohort. Similar mortality 
rates and refractory ICP deaths suggest that children with severe AHT may benefit from therapies 
including invasive monitoring and adherence to evidenced-based guidelines.
Keywords
pediatric traumatic brain injury; abusive head injury; comparative effectiveness research; pediatric 
neurocritical care; secondary injuries
Introduction
Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in children (1) 
and abusive head trauma (AHT) remains a mechanism of injury unique to children. Previous 
work has shown have shown worse outcomes in AHT children compared to other 
mechanisms of TBI (2, 3). It is unclear if this relationship is due to the age of these children 
(as AHT children are more likely to be ≤ 2 y) or if pathological mechanisms unique to AHT 
are responsible for the relationship (2, 4–6). With the large gap in our knowledge about the 
pathophysiology of AHT and the lack of evidence regarding treatments specific to children 
with such an injury, the current evidenced-based guidelines have been unable to make 
substantive recommendations regarding this unique population (7). This has negatively 
impacted the identification and development of therapeutic targets to improve outcome in 
this patient population and argues for our need to better understand children with AHT.
At present, AHT has recognizable differences in several clinical and pathophysiologic 
features. AHT can often include acceleration/deceleration forces, multiple injuries and a 
delay in presentation to medical care. Diffuse axonal injury, subdural hemorrhage (from 
shearing of bridging vessels) with some degree of hypoxia are commonly reported (8–10). A 
recent review found that AHT children - of all severities of injury - have 20% mortality and 
almost 50% permanent disability rates (11). Keenan and colleagues found children with 
AHT had worse outcomes at 1 year post-injury (12) and that children with AHT (i) were 
younger, (ii) had extracranial fractures, (iii) retinal hemorrhages, (iv) older injuries, (v) 
subdural hemorrhage, (vi) seizures and (vii) cerebral edema (13). In another study, only 15% 
of AHT patients had a good outcome at a mean of 8 years after injury whereas 40% had 
severe neurological impairment (14). Among children with AHT, risk factors for mortality 
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include low initial GCS score, retinal hemorrhage, intraparenchymal hemorrhage, and 
cerebral edema (15). Lastly, AHT is associated with financial, emotional and societal costs. 
Xiang and colleagues found that hospital charges for AHT patients to average approximately 
$30,000 (4). The average hospital costs for AHT in the U.S. was $69.6 million (16). This 
estimate did not consider ongoing medical needs which Lind and colleagues found that 83% 
of AHT children required at median follow-up of 8 y after injury (14). Survivors are 
estimated to exceed 24 disability adjusted life years (DALY), defined as years lost due to 
disability/death, while even mild AHT exceeds the burden estimated for children with severe 
burn injuries (17). Finally, AHT children incur medical costs years after their initial injury, 
an average of $47,952 in the 4 years following the event (18).
Due to the alarming consequences of AHT and severe limitations of our understanding of 
this population, we chose to analyze the first 200 children in the ADAPT Trial to better 
understand this population as rapidly as possible. In this analysis, we determined factors 
associated with AHT and the impact of AHT on mortality.
Methods
The ADAPT trial is a comparative effectiveness study of children with severe TBI funded 
via a cooperative agreement with NINDS (U01 NS081041). The overall goal of the study is 
to compare the effectiveness of strategies related to intracranial hypertension, secondary 
injuries and metabolic support in 1000 children from centers (n = 51) in the US, UK, Spain, 
the Netherlands, India, South Africa, Australia and New Zealand. All centers received 
Institutional Review Board approval (or equivalent) for performing the study and the 
University of Pittsburgh received IRB approval to coordinate the study. The study design of 
the ADAPT trial is strictly observational – sites care for children based on their local 
standards of care without interventions. Due to this study design and the need to minimize 
selection bias, all sites were granted permission by their IRB/Ethics Board to collect data 
regarding the acute hospitalization on all children who met inclusion criteria/exclusion 
criteria (inclusion: age < 18 y, diagnosis of severe TBI [Glasgow Coma Scale (GCS) score ≤ 
8], placement of intracranial pressure (ICP) monitor at study site; exclusion: pregnancy). 
Informed consent was obtained for follow-up activities including mortality assessments. 
Therefore, the subjects in this report represent consecutive eligible subjects admitted to 
study sites.
In this analysis, data from the first 200 subjects enrolled in the study (February 22, 2014 – 
December 22, 2014) were analyzed. The analysis was designed to determine factors 
associated with AHT and the role of AHT with mortality. This analysis was performed at 
this juncture because (i) the sample size of 200 is one of the larger populations of children 
with severe TBI in the literature to date and (ii) the desire to inform the pediatric 
neurotrauma community of compelling findings in a timely manner. Demographic 
characteristics, injury details, injury-related scores (Abbreviated Injury Scores [AIS], Injury 
Severity Scores [ISS], Pediatric Risk of Mortality [PRISM] III scores), prehospital events 
and resuscitation events were collected. Definitions of these variables are provided in the 
supplementary material. Mortality (defined as death within the study period – up to 1 year 
after ICP monitor placement) was collected as the outcome for this analysis. The cause of 
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death was stratified (multisystem trauma, refractory intracranial pressure, medical 
complications) and recorded from the medical record. Prehospital events were defined as 
events that occurred from the time the injury until presentation to the study hospital. 
Resuscitation events were defined as events that occurred from the time of admission to the 
study hospital until the ICP monitor was placed.
Data Stratification and Data Analysis
AHT was stratified based on the certainty of the clinicians at the clinical site regarding the 
diagnosis of AHT (Table 1). For this analysis, we combined “Probable AHT” and “Definite 
AHT” (defined as “AHT”) children and compared this group to those without suspicion of 
AHT (defined as “No AHT”). Children initially classified as “Possible AHT” were excluded 
from this analysis because the circumstances were too vague to categorize the subjects. The 
demographic and clinical characteristics are reported by subgroup as means ± SEM for 
continuous variables and percentages for discrete variables. T-tests were used to test the 
equality of the means across the group for continuous variable and chi-square tests were 
used to compare percentages for discrete variables. When test assumptions were not met, the 
non-parametric Wilcoxon test was used to compare between-group means and Fisher’s exact 
test was used to compare the distributions of percentages. The association of AHT with 
mortality was assessed using standard survival analyses techniques. A log-rank test was used 
to assess for differences between the two curves. To control for confounding effects, a multi-
variable Cox proportional hazards model was used to assess the independent association of 
AHT on mortality. A bivariate proportional hazards model was also estimated for 
comparison.
Results
There were a total of 190 children included in this analysis (10 were excluded as “possible 
AHT”). Of the 190 children, 35 were classified as AHT. Demographics are presented in 
Table 2. Those with AHT were younger (1.87 y ± 0.32 vs. 9.23 y ± 0.39, p < 0.001) and a 
greater proportion were female (54.3% vs. 45.7%, p = 0.032). There were 26 children from 
international study sites (defined as sites outside of the United States) and none were 
diagnosed with AHT. There was no difference in AIS and ISS scores between groups except 
for thoracic scores were lower in AHT children (Table 3). There was also no difference in 
GCS score (5.03 ± 0.32 vs. 5.32 ± 0.15, p = 0.354).
In the prehospital phase of care, children with AHT were more likely to have been 
transported from home (60% vs. 33.5%, p < 0.001), more likely to have apnea (34.3% vs. 
12.3%, p = 0.002) and seizures (28.6% vs. 7.7%, p < 0.001). There was no difference in 
rates of hypoxemia or hypotension between AHT and the non-AHT groups in the pre-
hospital care (2.9% vs. 7.1%, p = 0.61; 8.6% vs. 15.5%. p = 0.67; respectively). During the 
resuscitation phase of care, seizures were also more common in children with AHT (31.4% 
vs. 9.7%, p = 0.002; Table 4). There again was no difference observed between rates of 
hypoxemia and hypotension in AHT compared to non-AHT groups (5.7% vs. 3.2%, p = 
0.62; 34.3% vs. 29.0%, p= 0.54; respectively). Children with AHT received more 
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barbiturates (17.1% vs. 3.9%, p = 0.010) and had decreased hemoglobin levels (9.78 g/dl 
± 0.37 vs. 11.3 g/dl ± 0.15, p ≤ 0.001).
There was no difference in mortality between AHT and the non-AHT groups (25.7% vs. 
18.7% respectively; adjusted HR 1.758, p = 0.60 after adjustments, see Table 5). The 
majority of deaths in both groups were due to increased ICP (AHT, 66.7%; non-AHT, 
67.9%). PRISM III scores were not different between AHT and non-AHT groups (19.2 
± 3.26 vs. 17.2 ± 1.38, p = 0.25).
Discussion
In severe pediatric TBI, the diagnosis of child abuse – with its pathophysiological sequelae - 
can have implications on many factors that may affect outcome. Over the last several years, 
a knowledge gap has been identified regarding children with AHT within the literature, 
especially in terms of management and therapeutic targets. Given the lack of guideline-based 
recommendations for therapy specifically for severe AHT, insight into epidemiology, 
management, and outcome in severe AHT - particularly when ICP monitoring and ICP-
directed therapy is used - is desperately needed. AHT is more likely to include intracranial 
hemorrhage, damage in the craniocervical junction, respiratory compromise, shock and 
cerebral edema (19, 20). Predictors of poor outcome include depth of coma, cerebral edema, 
hypoxia-ischemia, PRISM scores, retinal/intraparenchymal hemorrhages (15, 21, 22). 
Indeed, AHT represents a distinct clinical and pathophysiologic entity of TBI.
Our study used the first 200 prospectively recruited children in the ADAPT trial, which 
focuses on severe TBI cases where ICP monitoring and ICP-directed management was used. 
While other series may have contained more AHT subjects, our report reflects consecutive 
patients cared for at more than 50 sites across the developed world – thereby reflecting a 
comprehensive examination of clinical care over approximately 1 year of patient screening. 
AHT victims have been consistently reported in the literature to be younger than children 
with accidental TBI (23–27), which our study confirmed. In contrast to most AHT cohorts, 
we found a female predominance in the population of AHT (3, 15, 16, 23, 24, 28–30). We 
found one other study that showed a female predominance in AHT (31). Our study differed 
from others in the literature in that included children all had ICP monitors placed – which 
may have altered the relationship between gender and AHT in some unexplained manner. 
One could speculate that gender may impact the injury response to explain the female 
predominance, but our study cannot support any conclusions for this hypothesis (32–34). 
There does not appear to be a cultural bias from international site enrollments, as we did not 
identify any children (male or female) from the international sites with AHT in this cohort.
We found that children with AHT were more likely to have seizures and apnea before arrival 
to the study hospital, and seizures were also more common during the resuscitation phase of 
care. These findings are consistent with a recent study by Greiner and colleagues that found 
over 25% of their population with AHT had non-convulsive seizures (35) as well as other 
reports (36, 37). A recent meta-analysis found that seizures and apnea were significantly 
associated with AHT, supporting our findings (27). Johnson and colleagues found that the 
majority of their AHT cohort had apnea prior to arrival at the hospital (38). Interestingly, 
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even though there was a high incidence of apnea in children with AHT in our study, there 
was no significant difference in hypoxemia between groups in both the pre-hospital and 
resuscitation phases. This may be in part due to the definition of “hypoxemia” used in the 
ADAPT trial, which is defined as a SaO2 < 90% for 30 minutes.
Finally, we found that children with AHT were more frequently transported from home. This 
finding is consistent with the presumption that caregivers of children with AHT may be 
perpetrators of the injury, thus being more reticent to activate the emergency medical system 
(13). While our data cannot provide information as to the circumstances surrounding these 
decisions, it does suggest that prehospital care of children with AHT may differ substantially 
from other children with TBI. Specifically, transport to the hospital by private vehicle 
without trained personnel could lead to the under-diagnosis/treatment of secondary insults. 
Differences in prevalence of seizures and apnea could either be explained by a delay in 
presentation for the AHT group, or by the fact that these groups are affected by different 
mechanisms of injury.
Since seizures were more common, it is not surprising that barbiturates were administered 
more often to the AHT group. We also found that children with AHT had decreased 
hemoglobin levels compared to accidental TBI. This could be explained by the younger age 
of children with AHT and their proximity in age to their physiological hemoglobin nadir (6 - 
8 weeks of age). Others have shown a decrease in hematocrit associated with AHT, and this 
finding was shown to be an important component to a decision rule in diagnosing AHT (31, 
39, 40). There was no difference in neurological exam except for the lowest recorded GCS 
score, which was decreased in the AHT group. Consistent with our GCS finding, Hymel and 
colleagues and Goldstein and colleagues found a similar relationship between lowest GCS 
score and AHT (19, 41). Finally, another study reported that children with AHT were more 
likely to have a GCS score of 3 - 8 (OR 2.99) as compared to children with accidental TBI 
(42).
In contrast to previous reports, we did not find a difference in mortality between the AHT 
and non-AHT groups. Previous studies have generally been limited by sample size, 
retrospective design and lack of control of confounding factors. Xiang and colleagues found 
the case mortality rate was 53.9 per 1000 patients with AHT compared to 1.6 per 1000 
patients with accidental TBI (4). There have been other reports of 3 – 6 fold increase in 
mortality rates in AHT when compared to accidental TBI (25, 26, 43). All of these studies 
have included all severities of injury and have not required an ICP monitor for inclusion. We 
believe that our data on children with severe AHT being monitored/treated for intracranial 
hypertension are of special importance because they represent children who were being 
treated in centers committed to care based on the published guidelines. We also found that a 
similar percentage of children died from refractory ICP in both groups. This is a novel and 
potentially important finding particularly given the well-known paucity of ICP monitoring in 
young children (some presumed to have AHT) reported by Bennett and colleagues (44). Our 
finding certainly suggests that victims of AHT have increased ICP and could likely benefit 
from ICP monitoring and ICP-directed therapy as others have suggested (45).
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Our study has limitations, including a relatively small sample size of AHT children. 
Nevertheless, we feel that this cohort from multiple centers remains valuable, particularly 
due to the large number of covariates available for analysis and the consecutive nature of 
subject enrollments. We believe that it is important to disseminate the current findings to the 
pediatric neurotrauma community to manage this important public health problem as the 
parent study is completed. A second limitation of the study is the reliance on site personnel 
to identify cases of definite and probable AHT. As sites may have different systems of 
detecting such a disorder, our study is necessarily reliant on the clinical sites for this 
determination. Third, our study is necessarily reliant on information from medical records, 
including reports from parents, regarding important aspects under study. In particular, our 
finding that prehospital apnea was common in children with AHT must take into account 
that many of these children were transported to the hospital from home – and the ability of 
caregivers to report physiological findings is limited. Nevertheless, we were able to identify 
that prehospital apnea was commonly found in children with AHT. Lastly, there is an 
unavoidable selection bias for children who received ICP monitoring as part of their clinical 
care. While this limits our overall understanding of AHT children with the entire spectrum 
of TBI severity, we believe that this intentional selection of children infers that ICP 
monitoring in AHT children can lead to similar mortality rates compared to children with 
accidental injuries.
In conclusion, we found a predominance of younger and female children within our AHT 
cohort of consecutive children across dozens of clinical sites in the developed world. 
Seizures and apnea occurred early, demonstrating the need for careful monitoring of children 
suspected of AHT. While there was no difference in mortality between groups, a similar 
percentage of children in both groups died from increased ICP, further suggesting AHT 
children might benefit from ICP monitoring and ICP-directed therapy.
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Table 1
Definition of Abusive Head Trauma within the ADAPT Trial
Likelihood of Abusive Head
Trauma (AHT)
Definition
None No evidence within the medical records that AHT is being considered
Possible AHT Clinical notes indicate that AHT is in the differential diagnosis of the treating team, but the diagnosis of AHT 
has not been made
Probable AHT Clinical notes indicate that the treating team believes that the child suffered from AHT
Definite AHT Confirmed diagnosis of intentional trauma and AHT is documented by a physician within the medical record
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